Dimethyl Fumarate

證據等級: L5

預測適應症: 10 個

Dimethyl Fumarate: From Relapsing-Remitting Multiple Sclerosis to Progressive Multiple Sclerosis

One-Sentence Summary

Dimethyl fumarate (DMF, marketed as Tecfidera®) is an oral immunomodulator globally approved for the treatment of relapsing-remitting multiple sclerosis (RRMS) in the US, EU, and Japan. The TxGNN model predicts it may be effective for Progressive Multiple Sclerosis, with 18 clinical trials and 19 publications currently supporting this direction, including a completed Phase 2 RCT that directly enrolled primary progressive MS patients.

Quick Overview

Item	Content
Original Indication	Relapsing-remitting multiple sclerosis (RRMS)
Predicted New Indication	Progressive Multiple Sclerosis
TxGNN Prediction Score	90.67%
Evidence Level	L2
Singapore Market Status	Not marketed
Number of Registrations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

DMF's core mechanism operates through the Nrf2 (Nuclear factor erythroid 2-related factor 2) pathway: upon activation, Nrf2 induces antioxidant enzymes including HO-1 and NQO1, substantially reducing neuronal oxidative stress. Concurrently, DMF inhibits NF-κB signaling, suppresses pro-inflammatory cytokines (IL-6, TNF-α), and shifts the immune phenotype from Th1 toward Th2 while reducing circulating CD8+ T cell counts.

This mechanistic profile maps closely onto the pathological substrate of progressive MS. Unlike RRMS — which is dominated by episodic immune-mediated attacks on the myelin sheath — progressive MS (both primary and secondary forms) is characterized by sustained, smouldering oxidative neurodegeneration, mitochondrial dysfunction, and slowly expanding grey matter lesions in which acute inflammation plays a secondary role. DMF's Nrf2/antioxidant arm is theoretically well-positioned to address this pathway. However, since fewer acute inflammatory lesions are present in progressive disease, the immunomodulatory benefit expected in RRMS is anticipated to be attenuated.

A completed Phase 2 randomized placebo-controlled trial (NCT02959658, n=54) directly tested DMF in primary progressive MS. Although the trial did not meet its pre-specified primary endpoint (reduction in CSF neurofilament light chain concentration at 48 weeks), a subsequent open-label extension (PMID 36586351) and real-world observational cohort data (PMID 33996142) provide exploratory signals that DMF may still slow neurodegeneration in this population — supporting the biological plausibility of the TxGNN prediction and justifying further investigation with an adequately powered trial.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT02959658	Phase 2	Completed	54	Randomized placebo-controlled trial directly in primary progressive MS (PPMS). Primary endpoint (CSF neurofilament light chain reduction) not met, but open-label extension (PMID 36586351) provides longer-term exploratory data. The only completed RCT of DMF specifically in PPMS.
NCT03092544	Phase 4	Unknown	57	Investigates indirect neuroprotective mechanisms of Tecfidera® (DMF) in both RRMS and progressive MS patients, including gut microbiome interactions; directly supports the mechanistic rationale for progressive disease.
NCT02430532	Phase 3	Terminated	58	BG00012 (DMF) vs placebo in secondary progressive MS (SPMS) to delay non-relapse-related disability progression. Terminated early due to slow enrollment; contextual importance remains high as the only Phase 3 attempt in SPMS.
NCT02683863	Phase 4	Completed	20	Pharmacokinetic study examining whether DMF or its metabolite monomethyl fumarate (MMF) penetrates the CNS in SPMS patients via CSF sampling; addresses blood-brain barrier penetration relevant to neuroprotection claims.
NCT07138833	Phase 4	Not Yet Recruiting	50	Prospective open-label evaluation of DMF enteric-coated capsules in relapsing MS including active secondary progressive MS (SPMS); trial start expected 2025.
NCT03535298	Phase 4	Active, Not Recruiting	800	DELIVER-MS: large comparative trial assessing whether early high-efficacy DMT (including DMF) improves long-term prognosis in RRMS; indirectly informs progressive MS prevention potential.
NCT03193866	N/A	Completed	3526	COMBAT-MS: population-based prospective cohort comparing DMF and other DMTs including rituximab over 5 years in RRMS; provides large-scale real-world effectiveness and safety benchmarks.
NCT03500328	N/A	Active, Not Recruiting	900	TREAT-MS: pragmatic trial comparing early aggressive therapy vs escalation approach for MS disability prevention; DMF serves as a reference comparator arm.
NCT04676204	N/A	Enrolling by Invitation	323	STATURE: prospective multi-site study on treatment burden and adherence across six oral DMTs including DMF; informs real-world tolerability relevant to progressive MS populations.
NCT02739542	Phase 4	Completed	87	ARISE: randomized double-blind trial of DMF in radiologically isolated syndrome (RIS) to delay conversion to clinical MS; provides data on DMF efficacy at the earliest identifiable disease stage.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
34429340	2021	RCT (Phase 2)	Neurology® Neuroimmunology & Neuroinflammation	Primary publication of NCT02959658 RCT of DMF vs placebo in PPMS (n=54); primary endpoint (CSF NFL reduction) not met, but safety profile acceptable. The most directly relevant trial evidence for this repurposing.
36586351	2023	Open-Label Extension	Multiple Sclerosis and Related Disorders	Open-label extension of the PPMS Phase 2 RCT; provides longer-term exploratory efficacy and safety data on DMF in primary progressive MS beyond the initial 48-week placebo-controlled phase.
33996142	2021	Real-World Cohort	Multiple Sclerosis Journal – Experimental, Translational and Clinical	Retrospective cohort analysis of DMF effectiveness and safety specifically in the progressive MS population; limited sample size but directly addresses the repurposing question with real-world data.
38174776	2024	Network Meta-Analysis	Cochrane Database of Systematic Reviews	Updated Cochrane NMA comparing all immunomodulators and immunosuppressants for RRMS; most comprehensive comparative efficacy reference for DMF positioning in the MS treatment landscape.
38321317	2024	Systematic Review + Meta-Analysis	Drug Safety	Systematic review and meta-analysis of drug-induced PML including DMF; quantifies absolute risk and identifies key risk factors (lymphopenia, JC virus antibody status). Critical safety reference.
29686116	2018	Clinical Practice Guideline	Neurology	AAN practice guideline on DMTs for adult MS; formally endorses DMF as first-line therapy for RRMS; provides regulatory and clinical context for expanding to progressive indications.
25900414	2015	Cochrane Review	Cochrane Database of Systematic Reviews	Original Cochrane systematic review confirming DMF efficacy in RRMS (approved by FDA and EMA); establishes the evidence base from which progressive MS extrapolation is being attempted.
33091427	2021	Literature Review	Pharmacology & Therapeutics	In-depth mechanistic review of DMF-induced lymphopenia and its molecular basis; explains why persistent grade ≥3 lymphopenia elevates PML risk. Essential for safety monitoring protocol design.
32808554	2022	Case Series / Safety Study	Multiple Sclerosis (Houndmills)	Clinical characterization of 9 PML cases in DMF-treated MS patients; PML incidence estimated at 0.02 per 1,000 patients; sustained lymphopenia identified as the dominant risk factor.
27433310	2016	Review	Therapeutic Advances in Chronic Disease	Comprehensive review of DMF after 2+ years of real-world use across >190,000 patients; covers post-marketing safety signals, subgroup efficacy analyses, and patient selection guidance.

Singapore Market Information

Dimethyl fumarate (DB08908) is currently not registered in Singapore. There are no product authorizations on record with HSA.

For reference: DMF is approved internationally as Tecfidera® (Biogen) for RRMS in the US (FDA, March 2013), EU (EMA, January 2014), and Japan (PMDA, December 2016). Any Singapore deployment would require a new HSA New Drug Application submission.

Safety Considerations

Please refer to the package insert for safety information.

Key risk identified from the evidence literature (independent of package insert data):

Lymphopenia and PML risk: DMF causes progressive, dose-dependent lymphopenia. Persistent grade ≥3 lymphopenia (absolute lymphocyte count <0.5 × 10⁹/L sustained for >6 months) substantially increases the risk of progressive multifocal leukoencephalopathy (PML) — a potentially fatal opportunistic CNS infection caused by JC virus reactivation. PML incidence in DMF-treated patients is estimated at 0.02 per 1,000 patients (PMID 32808554). Routine lymphocyte count monitoring is mandatory; treatment discontinuation should be considered at defined thresholds.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: A completed Phase 2 RCT and real-world cohort data directly addressing progressive MS provide L2-level evidence, and the Nrf2/antioxidant neuroprotective mechanism offers a scientifically plausible rationale for targeting the oxidative neurodegeneration central to progressive MS — even though the Phase 2 primary endpoint was not met. DMF's established safety profile in >560,000 RRMS patients globally is a meaningful asset for any progressive indication development.

To proceed, the following is needed:

Regulatory pathway: Initiate HSA Singapore new drug application process; DMF currently has no local market authorization
MOA documentation: Resolve data gap by querying the DrugBank API for complete mechanism of action details (DB08908)
Safety monitoring protocol: Establish mandatory lymphocyte count monitoring schedule (baseline → monthly for first 6 months → every 3 months thereafter) with pre-defined discontinuation thresholds; include JC virus antibody screening prior to initiation
Package insert review: Obtain and parse the Tecfidera® US/EU SmPC or PMDA package insert for complete warnings and contraindications, to fill the current blocking data gap (DG001)
Trial design consideration: The existing Phase 2 (n=54) was underpowered; a Phase 2b/3 trial in secondary progressive MS (SPMS) with disability progression as the primary endpoint and NfL as a validated surrogate is needed before regulatory filing for a progressive indication
Biomarker strategy: Incorporate serum NfL monitoring (per PMID 35182510 methodology) as an early futility/efficacy signal in any prospective investigation
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.